ZIOP-XON Fundamental & Technical Discussion Board - “Immense therapeutic potential”—-NIH terminology - ZIOP-XON Fundamental & Technical Discussion Board - InvestorVillage
ZIOP-XON Fundamental & Technical Discussion Board
This is a semi-private group. You are free to browse messages, but you must be a member of this group to post messages. Join This Group

Group: ZIOP-XON Fundamental & Technical Discussion Board   /  Message Board  /  Read Message

 
 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  13716 of 14249  at  10/21/2019 10:19:49 AM  by

pharmionphil

The following message was updated on 10/21/2019 10:33:17 AM.

“Immense therapeutic potential”—-NIH terminology

Msg 111151 of 111151 at 10/21/2019 10:09:57 AM by

pharmionphil

edit | delete
The following message was updated on 10/21/2019 10:12:40 AM.


In response to msg 110104 by mymorningsong view thread
Re: “Immense therapeutic potential”
NIH comment on the patents.

There have been attempts to downplay and minimize the transfer here of course.

Par for the course.

Rec taking note of the following quote from the NIH over wiki aces,fudsters here.





T Cell Receptors (TCRs) Specific for Mutant p53

Mutations in tumor protein p53 are expressed in a variety of human cancers such as colon, pancreatic, breast, and non-small cell lung cancer. P53 acts as a tumor suppressor by regulating cell division and DNA repair. Mutations of p53 reduce or eliminate its regulatory functions, contributing to cancer formation and progression. Novel therapeutics are needed that specifically target p53 mutations, as small molecule inhibitors lack sequence specificity.

T cell receptors (TCRs) are proteins expressed on the surface of T lymphocytes that can recognize peptide antigens from infected and malignant cells in the context of human leukocyte antigen (HLA) molecules with exquisite specificity. Subsequent T cell activation leads to an immune response which aims to eliminate abnormal cells. TCRs may be further engineered to recognize specific tumor antigens. Adoptive transfer of these tumor antigen-specific TCR-engineered T cells into patients has been demonstrated as a promising cancer treatment strategy.

Researchers at the National Cancer Institute (NCI) identified T-cell receptors (TCRs) targeting a specific mutation in the p53 tumor suppressor, R175H, in the context of HLA-DRB1*13:01. The p53-R175H “hotspot” mutation occurs in ~4.5% of all cancers, and as such, is an attractive target for adoptive T cell immunotherapy. Normal tissue does not express the mutated p53 protein. Therefore, these TCRs are expected to specifically eliminate human cancer cells that express both the appropriate p53 mutant and HLA molecules upon adoptive transfer into patients. NCI researchers have shown that T cells with these TCRs can be purified and enriched from the peripheral blood leukocytes of cancer patients and respond to stimulation by p53-R175H synthetic peptides.

The Surgery Branch is seeking statements of capability or interest from parties interested in collaborating to further develop and/or license these TCRs targeting mutant p53 and the associated HLA molecule.



Potential Commercial Applications: Competitive Advantages:
Cellular immunotherapy against cancer
Treatment of various cancers expressing the p53-R175H mutant
Companion diagnostics based on detection of the p53-R175H mutation

p53-R175H is expressed in ~4.5% of all cancers and targeting this mutation has immense therapeutic potential
T cells targeting mutated p53 may be isolated from a patients’ own peripheral blood leukocyte pool and enriched or engineered for adoptive cell therapy


Development Stage:
Prototype

Related Invention(s):




Inventors:

Drew Deniger (NCI) ➽ more inventions...

Parisa Malekzadeh (NCI) ➽ more inventions...

Steven Rosenberg (NCI) ➽ more inventions...


Intellectual Property:
Application No. 62/867,619

Publications:
Malekzadeh P, et al. Neoantigen screening identified broad TP53 mutant immunogenicity in patients with epithelial cancers. PMID: 30714987
Deniger DC, et al. T-cell responses to TP53 “hotspot” mutations and unique neoantigens expressed by human ovarian cancers. PMID: 29853601

Collaboration Opportunity:
Licensing and research collaboration


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 23     Views: 695
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board


About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...